These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 9858319)

  • 1. Comparative study of the pharmacodynamic and pharmacologic effects of Betaseron and AVONEX.
    Williams GJ; Witt PL
    J Interferon Cytokine Res; 1998 Nov; 18(11):967-75. PubMed ID: 9858319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up.
    Knobler RL; Greenstein JI; Johnson KP; Lublin FD; Panitch HS; Conway K; Grant-Gorsen SV; Muldoon J; Marcus SG; Wallenberg JC
    J Interferon Res; 1993 Oct; 13(5):333-40. PubMed ID: 8301153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum IFN neutralizing antibodies and neopterin levels in a cross-section of MS patients.
    Cook SD; Quinless JR; Jotkowitz A; Beaton P;
    Neurology; 2001 Sep; 57(6):1080-4. PubMed ID: 11571337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I study of recombinant interferon-beta in patients with advanced malignant disease.
    Ravandi F; Estrov Z; Kurzrock R; Breitmeyer JB; Maschek BJ; Talpaz M
    Clin Cancer Res; 1999 Dec; 5(12):3990-8. PubMed ID: 10632330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequency and magnitude of interferon β neutralizing antibodies in the evaluation of interferon β immunogenicity in patients with multiple sclerosis.
    Grossberg SE; Oger J; Grossberg LD; Gehchan A; Klein JP
    J Interferon Cytokine Res; 2011 Mar; 31(3):337-44. PubMed ID: 21226608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose and frequency of interferon treatment matter--INCOMIN and OPTIMS.
    Durelli L
    J Neurol; 2003 Dec; 250 Suppl 4():IV9-IV14. PubMed ID: 14712396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of the biologic activity of two recombinant IFN-beta preparations used in the treatment of relapsing-remitting multiple sclerosis.
    Antonetti F; Finocchiaro O; Mascia M; Terlizzese MG; Jaber A
    J Interferon Cytokine Res; 2002 Dec; 22(12):1181-4. PubMed ID: 12581490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and pharmacodynamics of IFN-beta 1a in healthy volunteers.
    Buchwalder PA; Buclin T; Trinchard I; Munafo A; Biollaz J
    J Interferon Cytokine Res; 2000 Oct; 20(10):857-66. PubMed ID: 11054273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
    Schwid SR; Panitch HS
    Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human biologic response modification by interferon in the absence of measurable serum concentrations: a comparative trial of subcutaneous and intravenous interferon-beta serine.
    Goldstein D; Sielaff KM; Storer BE; Brown RR; Datta SP; Witt PL; Teitelbaum AP; Smalley RV; Borden EC
    J Natl Cancer Inst; 1989 Jul; 81(14):1061-8. PubMed ID: 2472488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and pharmacodynamics of recombinant human interferon-beta in healthy male volunteers.
    Salmon P; Le Cotonnec JY; Galazka A; Abdul-Ahad A; Darragh A
    J Interferon Cytokine Res; 1996 Oct; 16(10):759-64. PubMed ID: 8910759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and antiviral activity of recombinant human interferon-beta ser17 in African green monkeys.
    Chiang J; Gloff CA; Soike KF; Williams G
    J Interferon Res; 1993 Apr; 13(2):111-20. PubMed ID: 8509658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transfer of interferon β-1a into human breastmilk.
    Hale TW; Siddiqui AA; Baker TE
    Breastfeed Med; 2012 Apr; 7(2):123-5. PubMed ID: 21988602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advancing treatment with interferon beta-1b (Betaferon/Betaseron) in the next decade--thinking beyond the standard dose.
    Cook SD
    J Neurol; 2003 Dec; 250 Suppl 4():IV15-20. PubMed ID: 14712397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamic comparison of single doses of IFN-beta1a and IFN-beta1b in healthy volunteers.
    Stürzebecher S; Maibauer R; Heuner A; Beckmann K; Aufdembrinke B
    J Interferon Cytokine Res; 1999 Nov; 19(11):1257-64. PubMed ID: 10574618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
    Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
    Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization and quantitation of aggregates and particles in interferon-β products: potential links between product quality attributes and immunogenicity.
    Barnard JG; Babcock K; Carpenter JF
    J Pharm Sci; 2013 Mar; 102(3):915-28. PubMed ID: 23233295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A robust type I interferon gene signature from blood RNA defines quantitative but not qualitative differences between three major IFNβ drugs in the treatment of multiple sclerosis.
    Harari D; Orr I; Rotkopf R; Baranzini SE; Schreiber G
    Hum Mol Genet; 2015 Jun; 24(11):3192-205. PubMed ID: 25721402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Open trial of the effectiveness of interferon beta 1a (Avonex) in multiple sclerosis. Clinical assessment using motor coordination tests].
    Selmaj K; Członkowska A; Kwieciński H; Losy J; Podemski R; Stelmasiak Z
    Neurol Neurochir Pol; 2003; 37(6):1163-83. PubMed ID: 15174231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of interferon beta-1a dose frequency on PBMC cytokine secretion and biological effect markers.
    Rothuizen LE; Buclin T; Spertini F; Trinchard I; Munafo A; Buchwalder PA; Ythier A; Biollaz J
    J Neuroimmunol; 1999 Sep; 99(1):131-41. PubMed ID: 10496186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.